Supernus Accounts Payable from 2010 to 2024

SUPN Stock  USD 30.26  0.31  1.04%   
Supernus Pharmaceuticals Accounts Payable yearly trend continues to be very stable with very little volatility. Accounts Payable is likely to drop to about 1.9 M. Accounts Payable is the amount Supernus Pharmaceuticals owes to suppliers or vendors for products or services received but not yet paid for. It represents Supernus Pharmaceuticals' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2008-12-31
Previous Quarter
3.4 M
Current Value
M
Quarterly Volatility
34.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many exotic indicators such as Price To Sales Ratio of 2.47, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Supernus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Supernus Pharmaceuticals Technical models . Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Latest Supernus Pharmaceuticals' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Supernus Pharmaceuticals over the last few years. An accounting item on the balance sheet that represents Supernus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Supernus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Supernus Pharmaceuticals' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Supernus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Supernus Accounts Payable Regression Statistics

Arithmetic Mean24,981,815
Geometric Mean9,429,216
Coefficient Of Variation154.39
Mean Deviation29,068,474
Median8,055,000
Standard Deviation38,568,279
Sample Variance1487.5T
Range115.8M
R-Value0.41
Mean Square Error1328.9T
R-Squared0.17
Significance0.13
Slope3,560,574
Total Sum of Squares20825.2T

Supernus Accounts Payable History

20241.9 M
2023M
202296.3 M
2021117.7 M
202078.9 M
201910.1 M
20183.2 M

About Supernus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts PayableM1.9 M

Supernus Pharmaceuticals Investors Sentiment

The influence of Supernus Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Supernus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Supernus Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bonds Directory
Find actively traded corporate debentures issued by US companies
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.